Table 3.
Multivariate analysis of overall survival in patients with hepatocellular carcinoma (n = 537).
| Overall survival |
||
|---|---|---|
| HR (95% CI) | P | |
| Serum HbsAg | ||
| Negative | 1.00 | |
| Positive | 1.81(1.33–7.62) | 0.047 |
| Serum HbeAg | ||
| Negative | 1.00 | |
| Positive | 2.34(1.49-6.01) | 0.027 |
| Liver cirrhosis | ||
| Absent | 1.00 | |
| Present | 1.84(1.21-4.37) | 0.045 |
| Intrahepatic metastasis | ||
| Not observed | 1.00 | |
| Observed | 239 (1.36–5.18) | 0.039 |
| TNM stage | ||
| I + II | 1.00 | |
| III + IV | 2.44(1.61-6.89) | 0.024 |
| PP2Ac expression | ||
| Low (≤10%) | 1.00 | |
| High (>10%) | 2.67(1.49-6.38) | 0.011 |
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
Significant P values are marked in bold.